Macrophage Therapy For Acute Liver Injury (MAIL)
The aim of this trial is to test the safety and tolerability of macrophage cell therapy in acute liver injury following paracetamol overdose.
Macrophage Therapy For Acute Liver Injury (MAIL) Trial: A Phase 1 Randomised, Blinded, Dose-Escalation Study to Evaluate Safety, Tolerability, and Activity of Allogeneic Alternatively Activated Macrophages (AAM) in Patients with Paracetamol-induced Acute Liver Injury.
Chief Investigator: Professor James Dear
Number and location of participating sites (by region/ country): Single Centre, Edinburgh Royal Infirmary
ISRCTN number: TBC
Funder: Medical Research Council
Start and End date
Of grant award: 01 December 2022 - 30 November 2025
Of recruitment: 01 Mat 2023 - 30 April 2025 (TBC)
Current Status: In set up
Sponsor: University of Edinburgh and NHS Lothian - https://www.accord.scot/
Professor James Dear, University of Edinburgh, Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, email@example.com
Anna Heye, ECTU, University of Edinburgh, level 2, NINE Edinburgh BioQuarter 9 Little France Road MAIL.Trial@ed.ac.uk
ECTU involvement: Trial Management, Statistics, Database